PNB-0408 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-22. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
After the fall of Tripoli in August 2011, only a few towns in western Libya such as Bani Walid, Sebha, and Sirte remained Gaddafist strongholds. Gaddafi was reportedly planning to catch up with his Sebha commander Ali Kanna's Tuareg forces and seek asylum in Burkina Faso. Instead, Gaddafi retreated to his hometown of Sirte, where he convened a meeting with his son Mutassim and intelligence chief Abdullah Senussi and learned that his youngest son Khamis had been killed by a NATO airstrike on 29 August. In the weeks that followed, Gaddafi continued to broadcast defiant audio messages through Syria-based Arrai TV. On 10 September, General Massoud Abdel Hafiz announced the formation of the Republic of Fezzan in Sebha, where Gaddafi would be president for life. Sebha fell on 22 September. Surrounding himself with bodyguards and a small entourage, including Mutassim, security chief Mansour Dhao, and defense minister Abu-Bakr Yunis Jabr, Gaddafi continually changed residences to escape NATO and NTC shelling, devoting his days to prayer and reading the Qur'an. On 20 October, Gaddafi recorded a farewell audio message for his family, later publicized by Al-Hadath, and then broke out of Sirte's District 2 in a joint civilian-military convoy. According to Dhao, it was a "suicide mission" as Gaddafi wanted to die in the Jarref Valley, close to where he was born. At around 08:30, NATO bombers attacked, destroying at least 14 vehicles and killing at least 53 people.
== N == David Nachmansohn (1899–1983). German biochemist at Columbia, responsible for elucidating the role of phosphocreatine in energy production in muscles. Member Natl. Acad. Sci. USA Joseph Needham FRS (1900–1995). British biochemist at Cambridge, historian and sinologist, noted for embryology and morphogenesis, and also in Chinese science. Eva J. Neer (1937–2000). American physician and biochemist at Harvard, who researched on G-protein cell biology. Member of the National Academy of Medicine. Joe Neilands (1921–2008). Canadian-born American biochemist and political activist at UC Berkeley, known for studies of microbial iron transport, and as author, with Paul K. Stumpf of Outlines of Enzyme Chemistry. Carl Neuberg (1877–1956). German biochemist at the University of Berlin, a pioneer in the study of metabolism. Michael Neuberger (1953–2013). British biochemist and immunologist at Cambridge University known for delineating the role of DNA deamination in immunity. Hans Neurath (1909–2002). American protein chemist at the University of Washington. He was the Founding editor of Biochemistry, which he edited for 30 years (1961–1991). Member Natl. Acad. Sci. USA. Eric Newsholme (1935–2011). British biochemist at the University of Oxford who specialised in human metabolism. Hermann Niemeyer (1918–1991). Chilean biochemist. National Prize of Science (Chile). Member of the Academy of Science of Chile. Marshall Warren Nirenberg (1927–2010).
In April 2022, Kardashian and her family returned to the television screens with their brand new reality television show, titled The Kardashians, after they left the E! Network to join Hulu. The show features Kardashian, alongside her sisters Kourtney, Kim, Kendall and Kylie, and mother Kris Jenner, it also features ex and current partners including Scott Disick, Travis Barker, Kardashian's ex Tristan Thompson, and Corey Gamble, with Kanye West making a guest appearance. The first season premiered on April 14, 2022, and its ten episodes can be streamed exclusively on Disney+. Later in 2022, the show was announced to be returning for a second season, which officially premiered on September 22, 2022. In late 2022, it was announced that the show had been officially renewed for a third season, set to premier in the first half of 2023. The third season officially aired on May 25, 2023. This was followed by a fourth season in September 2023, a fifth season in May 2024, and a sixth season in February 2025. In 2024, Kardashian announced the forthcoming release of her first ever video podcast series on X. She officially launched the podcast in January 2025, titled Khloe in Wonderland and it became available on all major audio streaming services. The show is produced weekly. In April 2025, Kardashian released her own popcorn brand called Khloud by Khloe Kardashian.
Sources: en.wikipedia.org
Phytoestrogens are involved in the synthesis of antifungal benzofurans and phytoalexins, such as medicarpin (common in legumes), and sesquiterpenes, such as capsidiol in tobacco. Soybeans naturally produce isoflavones, and are therefore a dietary source for isoflavones. Phytoestrogens are ancient naturally occurring substances, and as dietary phytochemicals they are considered to have coevolved with mammals. In the human diet, phytoestrogens are not the only source of exogenous estrogens. Xenoestrogens (novel, man-made), are found as food additives and ingredients, and also in cosmetics, plastics, and insecticides. Environmentally, they have similar effects as phytoestrogens, making it difficult to clearly separate the action of these two kind of agents in studies.
Assembly There are three main steps in the assembly of the final construct. First, the DNA parts are excised from the storage plasmid, giving a DNA fragment with BsaI overhangs on the 3' and 5' end. Next, each linker part is attached to its respective DNA part by incubating with T4 DNA ligase. Each DNA part will have a suffix and prefix linker part from two different linkers to direct the order of assembly. For example, the first part in the sequence will have L1P and L2S, while the second part will have L2P and L3S attached. The linker parts can be changed to change the sequence of assembly. Finally, the parts with the attached linkers are assembled into a plasmid by incubating at 50 °C. The 21 bp overhangs of the P and S linkers anneal and the final construct can be transformed into bacteria cells for cloning. The single stranded nicks are repaired in vivo following transformation, producing a stable final construct cloned into plasmids.
The enthalpy of sublimation, measured through testing of fermium alloys, is calculated at 33.8±3 kcal/mol (141.4±12.6 kJ/mol) derived from Second Law values, and 34.8 kcal/mol (145.6 kJ/mol) derived from Third Law values, both at 298 K. Through this, fermium is considered a divalent metal.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.